Glyco-neoepitopes (GNE) are new, tumor specific targets and their identification process
represents a technology platform to select for such epitopes. A GNE is defined as a
conformational combination of a modified (aberrant) glycosylation and the peptide backbone
of a tumor associated protein.
The combination of these two tumor-associated
antigens provides completely new structures (glyco-neoepitope) on the surface of a cell
which should be extremely tumor specific. Anti glyco-neoepitope antibody would therefore
recognize the carbohydrate indicative for a malignant transformation (e.g. Lewis Y, sTn etc.)
only in conjunction with a peptide structure on the tumor-associated glycoprotein. Even
glycoproteins with relatively high levels of expression on normal cells could be used as
new targets for immunotherapy as they are only recognized if expressed by cancer cells.